Learn more about the benefits and risks of taking Lovenox during pregnancy. While most pregnancies progress smoothly and without serious medical issues, pregnancy usually doesn’t come without some ...

Sanofi-Aventis said US sales of anti-thrombotic Lovenox were cut nearly in half by the launch of generic competition, an indication hospitals are showing little hesitation in using the copycat version ...

Sanofi-Aventis said today it lost a patent infringement case against two generic drug makers involving its top-selling product, the blockbuster bloodthinner Lovenox. Amphastar Pharmaceuticals and Teva ...

If you had any lingering doubt that biosimilar drugs will shake up the market for branded meds, here's a remedy. A generic version of Sanofi-Aventis' Lovenox blood thinner--enoxaparin--has surged onto ...

LONDON, June 5 (Reuters) - Doctors in Europe can continue to use Sanofi-Aventis SA's heparin medicine Lovenox, despite low levels of contamination found in some batches of the product, the European ...

The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis (DVT), a ...

Sanofi-Aventis has turned to the courts in a bid to stop Novartis unit Sandoz and partner Momenta Pharmaceuticals from selling a generic version of its blockbuster anti-clotting drug Lovenox.

Lovenox (enoxaparin) is a prescription drug used to prevent or treat certain types of blood clots. Lovenox’s cost may depend on factors such as your dosage, whether you have health insurance, and how ...

July 23, 2009 (Paris, France) — Administering unfractionated heparin (UFH) to patients already receiving enoxaparin--a common practice in the cath lab known as stack-on--results in overanticoagulation ...

Uninsured people who paid out of pocket for the anticoagulant drug Lovenox may be eligible for a payment from a $120 million proposed settlement in a dispute between Nashville General Hospital and two ...

Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb and Pfizer, was statistically superior to Sanofi-Aventis' Lovenox (enoxaparin) in reducing the incidence of venous ...

The optimal strategy for thromboprophylaxis after major joint replacement has not been established. Low-molecular-weight heparins such as enoxaparin predominantly target factor Xa but to some extent ...